Lucence: Unlocking Precision Medicine with Rapid TissueMARK™
Cancer treatment has entered a new era of precision medicine, yet traditional tissue profiling methods often fail to maximize therapeutic opportunities for patients. Rapid TissueMARK™ is here to change that by providing an accurate, fast, and cost-effective solution for genomic alteration detection. It integrates next-generation sequencing (NGS) and microsatellite instability (MSI) testing, ensuring that more patients receive the targeted therapies they need.
Broader Biomarker Coverage for Targeted Therapies
- Covers 7 major tumor types, ensuring comprehensive applicability.
- Detects over 50 DNA/RNA genomic alterations in FFPE tissue.
- More FDA-approved biomarkers compared to conventional NGS testing.
- 0.9% detection threshold, significantly improving sensitivity versus the standard 5% threshold.
Faster Turnaround for Critical Treatment Decisions
- Results available in just 5 working days, allowing physicians to make timely treatment decisions.
Cost-Effective and Sample-Saving Approach
- 34% cost savings by integrating mutation NGS and MSI for immunotherapy.
- No sample splitting required, preserving tissue for further analyses.
- Saves on slide-cutting costs, making the process more efficient and patient-friendly.
Maximising Patient Eligibility for Targeted Therapies
- Traditional tissue profiling methods cause 50% of eligible cancer patients to miss out on targeted treatments.
- Rapid TissueMARK™ identifies 1 in 6 additional patients who qualify for FDA-approved targeted therapies compared to conventional NGS testing.
Why Choose Rapid TissueMARK™?
1. Targeted Cancer Treatment
Rapid TissueMARK™ delivers a cost-effective solution that meets the highest medical standards. It is designed to detect FDA and CDL-approved genetic biomarkers for optimal treatment strategies, making it a critical tool for oncologists and healthcare professionals worldwide.
2. Recognised and Backed by Global Authorities
- Developed by Asia’s first company to obtain U.S. Medicare coverage for NGS cancer testing.
- Aligns with Singapore’s Cancer Drug List (CDL) regulations.
3. Validated by Leading Research and Clinical Data
- Based on rigorous data comparisons showing a significant improvement in biomarker detection efficiency.
- Supported by leading clinical studies such as Sadik et al. J Clin Oncol Precision Oncology (2022).
Who Can Benefit from Rapid TissueMARK™?
This cutting-edge genomic testing technology is suitable for:
- Newly diagnosed cancer patients, to determine the most effective treatment pathway from the start.
- Patients with recurrent or metastatic disease, ensuring that evolving mutations are detected for timely intervention.
- Patients not responding to standard-of-care treatments, providing additional targeted therapy options based on precise genetic insights.
How Rapid TissueMARK™ Works
- Tissue Sample Collection: FFPE tissue samples are used, eliminating the need for fresh biopsies.
- Comprehensive NGS + MSI Testing: Covers all essential genetic biomarkers, including those approved by the FDA and CDL.
- Superior Detection Sensitivity: With a 0.9% detection limit, it surpasses traditional NGS thresholds, identifying clinically relevant mutations that could be missed otherwise.
- Fast & Reliable Reporting: In just 5 working days, physicians receive a detailed report outlining the detected alterations and potential treatment options.
- Actionable Insights for Treatment Planning: Ensuring that patients receive precision-targeted therapies without unnecessary delays.
The Science Behind Rapid TissueMARK™
Traditional genomic testing methods often come with limitations, particularly in detecting low-frequency mutations. Rapid TissueMARK™ leverages advanced sequencing techniques to overcome these barriers, offering unparalleled accuracy and efficiency.
Key Scientific Advantages:
- Lower Detection Threshold (0.9%): Identifies rare but critical mutations that conventional tests miss.
- Integrated MSI Testing: Included by default, unlike other tests where it is an expensive add-on.
- Validated Across 7 Major Tumor Types: Including lung, colorectal, breast, gastric, liver, pancreatic, and ovarian cancers.
Real-World Impact: Enhancing Patient Outcomes
The ability to identify key genetic biomarkers earlier leads to better treatment decisions, improved patient responses, and increased access to innovative therapies. Rapid TissueMARK™ is already making a difference in clinical settings by:
- Improving survival rates through early and precise biomarker detection.
- Reducing the financial burden of expensive add-on tests.
- Optimizing sample use, avoiding unnecessary biopsies and preserving tissue for future testing.
Why Screen for Cancer Early?
1. Early Detection Leads to Better Outcomes
Cancer that is detected in its early stages is often more treatable, with less aggressive treatments needed. Early-stage cancers are typically localised and have not yet spread to other organs, making surgery, radiation, and other treatments more effective. This improves the chances of remission and long-term survival.
2. Cancer is the Number 1 Killer
Cancer is one of the leading causes of death worldwide, surpassing many other chronic diseases. It affects millions of people every year, contributing to a high burden on healthcare systems and families. Early detection helps reduce mortality rates and improves overall public health outcomes.
3. 4 in 5 Cancer Deaths Are Not Covered by Recommended Screening
Many people who die from cancer were not screened according to recommended guidelines. This means their cancers were detected too late, when treatment options were limited, and the disease had already advanced. Increasing awareness and access to routine screenings can significantly reduce preventable deaths.
4. 5-Year Survival is Higher with Early Detection
Survival rates are significantly better when cancer is diagnosed at an early stage. For example, the five-year survival rate for localized breast cancer is over 90%, but for metastatic breast cancer, it drops dramatically. The same trend is seen across various cancer types, emphasizing the importance of regular screenings.
FAQ
Rapid TissueMARK™ is an advanced AI-driven digital pathology solution designed to enhance tissue annotation and analysis. It helps pathologists and researchers achieve precise tumor identification, reducing variability and improving efficiency in oncology diagnostics.
Rapid TissueMARK™ uses artificial intelligence to automate and standardize the detection of tumor and non-tumor regions in tissue samples. This minimizes human subjectivity, enhances reproducibility, and accelerates decision-making in precision oncology.
Rapid TissueMARK™ is valuable for pathologists, oncologists, and researchers working in precision medicine, digital pathology, and clinical trials. It is particularly beneficial in hospitals, diagnostic labs, and pharmaceutical companies focused on cancer research and treatment.